INSILICO (03696) plans to contribute RMB302.5 million to participate in establishing an investment fund.

INSILICO (03696) announced that on November 3, 2026, INSILICO Shanghai and Insilico Pudong entered into a partnership agreement with Value Partners Shenzhen, Shanghai Pudong Construction, and Hanchen Lanxi for the establishment of a fund. The fund's total subscribed capital contribution is RMB610 million, of which the Group plans to contribute a total of RMB302.5 million. Upon completion of establishment, the fund will not become a subsidiary of the Company, and its financial results will not be consolidated into the Group's accounts. The fund is named Insilico Pudong Value Partners (Shanghai) Private Investment Fund Partnership (Limited Partnership). The fund shall primarily invest in growth-stage companies (from Series A to pre-IPO stage) in relevant fields such as biopharmaceuticals, life sciences, artificial intelligence and their interdisciplinary applications. The fund may also subscribe for shares issued by listed companies in the above industries to specific investors, or acquire shares of such listed companies through block trades, negotiated transfers, or other non-public methods permitted by applicable regulations, provided that it shall not participate in centralized bidding transactions on stock exchanges. The fund may also invest in convertible bonds with equity conversion rights, convertible bonds issued or traded privately, and other investment instruments of an equity investment nature. Participating in the fund aligns with the Group's strategic direction and will enable the Group to participate in growth opportunities arising from the continued development and innovation in the biopharmaceutical and life sciences sectors.